Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 267Neoplasms 177Colorectal Neoplasms 133Stomach Neoplasms 107Uterine Cervical Neoplasms 96Carcinoma, Non-Small-Cell Lung 89Prostatic Neoplasms 83Lung Neoplasms 78Carcinoma, Hepatocellular 73Rectal Neoplasms 64Ovarian Neoplasms 54Esophageal Neoplasms 53Pancreatic Neoplasms 52Colonic Neoplasms 52Recurrence 43Multiple Myeloma 39Neoplasm Metastasis 38Head and Neck Neoplasms 37Endometrial Neoplasms 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Motor Activity 34Melanoma 33Polycystic Ovary Syndrome 32Lymphoma 32Urinary Bladder Neoplasms 31Leukemia, Myeloid, Acute 30Thyroid Neoplasms 29Small Cell Lung Carcinoma 28Nasopharyngeal Carcinoma 25Lymphoma, Non-Hodgkin 25

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Castleman Disease × Clear all
NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

French National Agency for Research on AIDS and Viral Hepatitis

Phase 2 Terminated
25 enrolled
LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡